Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- FY2014 NHI Drug Pricing Reform –Part 1: New Rules Will Spur Efforts to Escape Dependence on Long-Listed Drugs, Spark Reorganization of Generic Industry
February 7, 2014
- FY2014 NHI Drug Pricing Reform –Part 2: Introduction of New Rule for Long-Listed Drugs, Elimination of Special Price Cuts Could Spark Shift to New Drugs, Use of AG Strategy
February 7, 2014
- Fiscal Impact Assessment for Key Premium Added to Chuikyo’s Supplementary Opinions for FY2014 Revision
February 6, 2014
- Submission of Draft Bills to Establish Japanese Version of US NIH Approved in Joint Session, “NIH” Will Not Be Part of Name
February 6, 2014
- PMDA’s Next 5-Year Plan to Embrace New Generic Unit, Benchmarks for Review Time
February 5, 2014
- Revised PAL, Pharmacists Law to Take Effect on June 12
February 5, 2014
- PAFSC’s Second Committee Backs Prostate Cancer Drug Enzalutamide
February 4, 2014
- PMDA Raises Caution about Using Factor Xa Inhibitor Xarelto, Citing Risk of Interstitial Pneumonia
February 4, 2014
- Wholesalers Call on Drug Makers to “Flexibly” Revise Invoice Prices
February 3, 2014
- PAFSC Committee Designates OTC PMS Treatment as First “Drug Requiring Guidance”
January 31, 2014
- Medical Fee Cuts Will Start from FY2014 to Improve Delivery Price Settlement Rates: Chuikyo
January 30, 2014
- Wary of Drug Price Negotiations Dragging Out into FY2014, MHLW to Survey Price Agreement Rate in March
January 30, 2014
- 2 Bills Related to the Establishment of a “Japanese NIH” to Be Submitted to the Diet in Early February
January 30, 2014
- 3 Entities Strike Codevelopment Deal for Adult TB Vaccines
January 29, 2014
- Rivaroxaban Under Review for Risk of Interstitial Pneumonia: PMDA
January 29, 2014
- PAFSC’s Second Committee to Review Taiho’s Novel Anticancer Agent on Feb. 3
January 28, 2014
- MHLW Setting Out on Development of iPS Tech-Based Cardiotoxicity Evaluation
January 28, 2014
- PAFSC’s First Committee Supports Approval of Second SGLT-2 Inhibitor Dapagliflozin
January 27, 2014
- FDA Bans Imports from Ranbaxy’s Toansa Plant, Daiichi Sankyo Promises Full Cooperation with FDA
January 27, 2014
- Health Minister Waits for Investigation Results on Novartis Involvement in “Sign” Study
January 27, 2014
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…